2. Hartman J, Granville M, Jacobson RE. The use of Vertiflex
® interspinous spacer device in patients with lumbar spinal stenosis and concurrent medical comorbidities. Cureus 2019; 11: e5374.
6. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6.
7. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-21.
8. Belamalem S, Khadmaoui A, Tailibi I, Benkirane R, Soulaymani BR, Soulaymani A. Use of measures of disproportionality in pharmacovigilance. Biotechnol (Rajkot) 2016; 12: 193-7.
9. Vivekanandan K, Tripathi A, Saurabh A, Kumar R, Kumar R, Prasad T, et al. Quantitative methods for the identification of signals for individual case safety reports in India. Ther Innov Regul Sci 2015; 49: 898-902.
11. Mo Z, Li D, Zhang R, Chang M, Yang B, Tang S. Comparative effectiveness and safety of posterior lumbar interbody fusion, Coflex, Wallis, and X-stop for lumbar degenerative diseases: a systematic review and network meta-analysis. Clin Neurol Neurosurg 2018; 172: 74-81.
12. Deer TR, Grider JS, Pope JE, Falowski S, Lamer TJ, Calodney A, et al. The MIST Guidelines: the Lumbar Spinal Stenosis Consensus Group guidelines for minimally invasive spine treatment. Pain Pract 2019; 19: 250-74.
14. Patel VV, Whang PG, Haley TR, Bradley WD, Nunley PD, Davis RP, et al. Superion interspinous process spacer for intermittent neurogenic claudication secondary to moderate lumbar spinal stenosis: two-year results from a randomized controlled FDA-IDE pivotal trial. Spine (Phila Pa 1976) 2015; 40: 275-82.
15. Bowers C, Amini A, Dailey AT, Schmidt MH. Dynamic interspinous process stabilization: review of complications associated with the X-Stop device. Neurosurg Focus 2010; 28: E8.
16. Ma X, Ma T, Dang X, Shi J, Niu N, Chang L, et al. Comparison of two interspinous spacers for treatment of moderate lumbar spinal stenosis: a meta-analysis of prospective randomized controlled trials. Int J Clin Exp Med 2017; 10: 4497-507.
17. Aggarwal P. Pyoderma gangrenosum adverse event with Rituximab use: a postmarketing pharmacovigilance analysis. Dermatol Ther 2020; 33: e13221.